Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018

Ruth Board¹, Rebecca Smittenear², Sarah Lawton², Hanhua Liu², Bukky Juwa², David Chao³, Pippa Corrie⁴

Table of Contents
Supplementary Table 1: Treatment duration ................................................................. 1
Supplementary Table 2: ICD-10 code names................................................................. 1
Supplementary Figure 1: Actual monthly prescriptions of immune checkpoint inhibitors… 2

Supplementary Table 1: Treatment durations (medians and ranges)

| Immunotherapy regimen | No. patients | Median treatment duration | Min   | Max   |
|-----------------------|--------------|----------------------------|-------|-------|
| Ipilimumab            | 724          | 68 [95% CI: 62, 76]        | 3     | 147   |
| Ipnivo                | 372          | 63 [95% CI: 62, 71]        | 7     | 440   |
| Nivolumab*            | 52           | 364                        | 27    | 657   |
| Pembrolizumab         | 1,174        | 192 [95% CI: 172, 216]     | 5     | 943   |

* Confidence intervals could not be produced as there were an insufficient number of events.

Supplementary Table 2: ICD-10 code names

| Toxicity Grouping | ICD codes | Code names                                      |
|-------------------|-----------|-------------------------------------------------|
| Colitis           | K521      | Toxic gastro-enteritis and colitis              |
|                   | K529      | Non-infective gastro-enteritis and colitis, unspecified |
|                   | A099      | Gastroenteritis and colitis of unspecified origin |
| Endocrinopathy    | E059      | Thyrotoxicosis, unspecified                     |
|                   | E222      | Syndrome of inappropriate secretion of antidiuretic hormone |
|                   | E230      | Hypopituitarism                                 |
|                   | E231      | Drug-induced hypopituitarism                    |
|                   | E236      | Other disorders of pituitary gland              |
|                   | E871      | Hypo-osmolality and hyponatraemia               |
| Diagnosis                        | Code | Description                                      |
|---------------------------------|------|--------------------------------------------------|
| Toxic liver disease with hepatic necrosis | K711 | Hepatitis                                       |
| Toxic liver disease with acute hepatitis | K712 | Toxic liver disease                            |
| Toxic liver disease with hepatitis, not elsewhere classified | K716 | Toxic liver disease                            |
| Toxic liver disease with other disorders of liver | K718 | Toxic liver disease                            |
| Autoimmune hepatitis | K754 | Inflammatory liver disease, unspecified |
| Nausea and vomiting | R11X | Nausea and vomiting                            |
| Constipation | K590 | Constipation                                    |

**Supplementary Figure 1**: Actual monthly prescriptions of (a) ipilimumab, (b) pembrolizumab, (c) nivolumab and (d) ipinivo recorded in the SACT database between April 2014 and 2018.